Reference Database

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.
Feng, Liqiang
Wang, Qian
Shan, Chao
Yang, Chenchen
Feng, Ying
Wu, Jia
Liu, Xiaolin
Zhou, Yiwu
Jiang, Rendi
Hu, Peiyu
Liu, Xinglong
Zhang, Fan
Li, Pingchao
Niu, Xuefeng
Liu, Yichu
Zheng, Xuehua
Luo, Jia
Sun, Jing
Gu, Yingying
Liu, Bo
Xu, Yongcun
Li, Chufang
Pan, Weiqi
Zhao, Jincun
Ke, Changwen
Chen, Xinwen
Xu, Tao
Zhong, Nanshan
Guan, Suhua
Yuan, Zhiming
Chen, Ling
Nature communications 2020 08 21;11: 4207

The rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1 × 10 viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation.

Forward to a friend